Free Trial

Editas Medicine (EDIT) News Today

$5.54
+0.07 (+1.28%)
(As of 07/12/2024 ET)
Editas Medicine logo with Medical background
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Hold" by Brokerages
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has been assigned a consensus rating of "Hold" from the ten brokerages that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation o
Editas Medicine logo with Medical background
Zacks Research Comments on Editas Medicine, Inc.'s Q3 2025 Earnings (NASDAQ:EDIT)
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Equities research analysts at Zacks Research reduced their Q3 2025 earnings estimates for shares of Editas Medicine in a research report issued on Tuesday, June 25th. Zacks Research analyst A. Chakraborty now anticipates that the company will po
Editas Medicine logo with Medical background
Los Angeles Capital Management LLC Takes Position in Editas Medicine, Inc. (NASDAQ:EDIT)
Los Angeles Capital Management LLC bought a new position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 147,883 shares of the company's stock, valued at approximately $1,097,000.
Editas Medicine logo with Medical background
Editas Medicine (NASDAQ:EDIT) Stock Rating Reaffirmed by Oppenheimer
Oppenheimer restated a "market perform" rating and issued a $12.00 target price on shares of Editas Medicine in a report on Tuesday.
Editas Medicine (NASDAQ:EDIT) Shares Up 14.2%
Editas Medicine (NASDAQ:EDIT) Stock Price Up 14.2%
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts
Shares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) have received an average recommendation of "Hold" from the eleven research firms that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation and five have given a buy r
Seven Eight Capital LP Acquires New Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)
Seven Eight Capital LP purchased a new position in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 146,345 shares of the company's stock, valued at approxima
Rafferty Asset Management LLC Sells 152,799 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)
Rafferty Asset Management LLC lowered its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 27.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 409,065 shares of the company's stock after selli
Insider Selling: Editas Medicine, Inc. (NASDAQ:EDIT) CEO Sells 12,191 Shares of Stock
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 12,191 shares of the business's stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $5.50, for a total transaction of $67,050.50. Following the completion of the sale, the chief executive officer now directly owns 315,279 shares of the company's stock, valued at $1,734,034.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Dimensional Fund Advisors LP Raises Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)
Dimensional Fund Advisors LP boosted its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 40.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,392,396 shares of the company's stock after buying an additional 690,366 shares durin
Brokers Issue Forecasts for Editas Medicine, Inc.'s FY2024 Earnings (NASDAQ:EDIT)
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Equities research analysts at Chardan Capital reduced their FY2024 earnings estimates for shares of Editas Medicine in a research report issued on Tuesday, May 28th. Chardan Capital analyst Y. Livshits now forecasts that the company will earn ($
Evercore ISI Trims Editas Medicine (NASDAQ:EDIT) Target Price to $7.00
Evercore ISI reduced their price target on Editas Medicine from $15.00 to $7.00 and set an "in-line" rating on the stock in a report on Thursday.
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by BNP Paribas Financial Markets
BNP Paribas Financial Markets cut its position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 60.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 215,011 shares of the company's stock after selling
Editas Medicine (NASDAQ:EDIT) Stock Price Up 11.6%
Editas Medicine (NASDAQ:EDIT) Stock Price Up 11.6%
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by Brokerages
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten analysts that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the
Editas Medicine (NASDAQ:EDIT) Shares Gap Up on Insider Buying Activity
Editas Medicine (NASDAQ:EDIT) Shares Gap Up on Insider Buying Activity
Insider Buying: Editas Medicine, Inc. (NASDAQ:EDIT) Director Buys 45,000 Shares of Stock
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) Director Jessica Hopfield acquired 45,000 shares of the stock in a transaction on Monday, May 13th. The stock was bought at an average price of $5.64 per share, with a total value of $253,800.00. Following the transaction, the director now directly owns 67,700 shares of the company's stock, valued at approximately $381,828. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Editas Medicine (NASDAQ:EDIT) Price Target Cut to $15.00
Citigroup reduced their price objective on Editas Medicine from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Thursday.
Editas Medicine (NASDAQ:EDIT) Releases Quarterly Earnings Results, Misses Expectations By $0.13 EPS
Editas Medicine (NASDAQ:EDIT - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.13). The firm had revenue of $1.10 million during the quarter, compared to the consensus estimate of $11.14 million. Editas Medicine had a negative return on equity of 42.95% and a negative net margin of 196.12%. The firm's revenue for the quarter was down 88.9% compared to the same quarter last year. During the same period last year, the company earned ($0.71) EPS.
Editas Medicine (NASDAQ:EDIT) Lifted to Equal Weight at Morgan Stanley
Morgan Stanley raised Editas Medicine from an "underweight" rating to an "equal weight" rating and set a $7.00 price target for the company in a report on Thursday.
Editas: Q1 Earnings Snapshot
What Wall Street expects from Editas Medicine's earnings
Editas Medicine (EDIT) to Release Earnings on Wednesday
Editas Medicine (NASDAQ:EDIT) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.
Get Editas Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

This is the type of environment we pray for… (Ad)

There is a situation in the market right now that requires your immediate attention. It involves a company that has $9 billion in cash, only $500,000 in debt, and a market cap of around $8 billion. This may not mean much to you right now.

I’ve spent months preparing this content for you.

EDIT Media Mentions By Week

EDIT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EDIT
News Sentiment

1.30

0.89

Average
Medical
News Sentiment

EDIT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EDIT Articles
This Week

3

3

EDIT Articles
Average Week

Get Editas Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:EDIT) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners